---
title: Drug management in obstetrics
videoId: gVClB0oHaHs
---

From: [[marrowmed]] <br/> 

## Postpartum Hemorrhage (PPH) Management

Various drugs are used for the management of postpartum hemorrhage (PPH) <a class="yt-timestamp" data-t="00:01:30">[00:01:30]</a>:

### Oxytocin
*   **Dose:** 20 International Units (IU) <a class="yt-timestamp" data-t="00:01:34">[00:01:34]</a>.
*   **Route:** Always given as intravenous (IV) infusion <a class="yt-timestamp" data-t="00:01:39">[00:01:39]</a>.
*   **Avoid:** Should not be given as IV bolus <a class="yt-timestamp" data-t="00:01:41">[00:01:41]</a> due to the risk of hypotension and cardiac arrest <a class="yt-timestamp" data-t="00:01:50">[00:01:50]</a>.
*   **Side Effects:** No specific side effects mentioned, but IV infusion should be administered in electrolyte-rich media <a class="yt-timestamp" data-t="00:02:01">[00:02:01]</a>. Giving it in electrolyte-deficient media (like dextrose 5%) can lead to water intoxication <a class="yt-timestamp" data-t="00:02:06">[00:02:06]</a>.

### Methergine (Methylergometrine)
*   **Dose:** 0.25 mg <a class="yt-timestamp" data-t="00:02:13">[00:02:13]</a>.
*   **Route:** Intramuscular (IM) <a class="yt-timestamp" data-t="00:02:14">[00:02:14]</a>.
*   **Contraindications:**
    *   After the delivery of the first twin <a class="yt-timestamp" data-t="00:02:20">[00:02:20]</a>.
    *   Organic heart disease <a class="yt-timestamp" data-t="00:02:33">[00:02:33]</a>.
    *   Peripheral [[Medical and Surgical Management of Vascular Diseases | vascular disease]] <a class="yt-timestamp" data-t="00:02:44">[00:02:44]</a>.
    *   Eclampsia/preeclampsia <a class="yt-timestamp" data-t="00:02:46">[00:02:46]</a>.
    *   Rh-negative pregnancy <a class="yt-timestamp" data-t="00:02:50">[00:02:50]</a>.
*   **Side Effects:** Administering Methergine intravenously can lead to hypertension <a class="yt-timestamp" data-t="00:02:56">[00:02:56]</a>.

### Carbetocin
*   **Use:** Synthetic oxytocin used in the active management of the third stage of labor <a class="yt-timestamp" data-t="00:03:04">[00:03:04]</a>.
*   **Note:** Not used in the management of PPH <a class="yt-timestamp" data-t="00:03:12">[00:03:12]</a>.

### Misoprostol (PGE1)
*   **Dose:**
    *   WHO recommendation: 800 micrograms (mcg) <a class="yt-timestamp" data-t="00:03:19">[00:03:19]</a>.
    *   ACOG recommendation for PPH management: 600 to 1000 mcg <a class="yt-timestamp" data-t="00:03:27">[00:03:27]</a>.
*   **Route:**
    *   WHO: Sublingually or orally <a class="yt-timestamp" data-t="00:03:22">[00:03:22]</a>.
    *   ACOG: Additionally recommends per rectal route <a class="yt-timestamp" data-t="00:03:30">[00:03:30]</a>.
*   **Contraindications:** Previous history of cesarean section <a class="yt-timestamp" data-t="00:03:41">[00:03:41]</a>. Not contraindicated in asthmatics <a class="yt-timestamp" data-t="00:03:45">[00:03:45]</a>.
*   **Side Effects:** Dose-related hypothermia and shivering <a class="yt-timestamp" data-t="00:03:48">[00:03:48]</a>.

### Carboprost (Dinoprost, HMIT) (PGF2 Alpha)
*   **Dose:** 250 mcg IM, repeated every 15 to 90 minutes <a class="yt-timestamp" data-t="00:03:57">[00:03:57]</a>.
*   **Maximum Dose:** Up to eight doses (2 mg total) <a class="yt-timestamp" data-t="00:04:04">[00:04:04]</a>.
*   **Contraindications:**
    *   Bronchial asthma <a class="yt-timestamp" data-t="00:04:09">[00:04:09]</a>.
    *   Pulmonary hypertension <a class="yt-timestamp" data-t="00:04:11">[00:04:11]</a>.
    *   Amniotic fluid embolism <a class="yt-timestamp" data-t="00:04:12">[00:04:12]</a>.
*   **Side Effects:** Diarrhea <a class="yt-timestamp" data-t="00:04:15">[00:04:15]</a>.

### Tranexamic Acid
*   **Dose:** 1 g <a class="yt-timestamp" data-t="00:04:24">[00:04:24]</a>.
*   **Use:** Used in PPH management in addition to other drugs <a class="yt-timestamp" data-t="00:04:26">[00:04:26]</a>.

## [[Magnesium sulfate uses in prenatal care | Magnesium Sulfate]] for Preeclampsia/Eclampsia

[[Magnesium sulfate uses in prenatal care | Magnesium sulfate]] is an anti-convulsant drug, not an anti-hypertensive drug <a class="yt-timestamp" data-t="00:38:31">[00:38:31]</a>. It is a centrally acting drug with a low therapeutic range (4 to 7 mEq/L) <a class="yt-timestamp" data-t="00:38:36">[00:38:36]</a>.

### Prichard Regimen
*   **Loading Dose:**
    *   IM: 10 g of 50% magnesium sulfate solution (5 g in each buttock) <a class="yt-timestamp" data-t="00:38:48">[00:38:48]</a>.
    *   IV: 4 g of 20% magnesium sulfate <a class="yt-timestamp" data-t="00:38:56">[00:38:56]</a>.
*   **Preparation for IV Dose:** To prepare 4g of 20% solution from a 50% solution (1g/2ml ampule), take 4 ampules (8ml) and add 12ml of normal saline to make a 20ml solution <a class="yt-timestamp" data-t="00:39:52">[00:39:52]</a>.

### Maintenance Dose
*   **Dose:** 5 g of 50% [[Magnesium sulfate uses in prenatal care | Magnesium sulfate]] IM <a class="yt-timestamp" data-t="00:41:09">[00:41:09]</a>.
*   **Frequency:** Every 4 hours <a class="yt-timestamp" data-t="00:41:14">[00:41:14]</a>.
*   **Duration:** Until 24 hours after vaginal delivery or 24 hours after the last seizure, whichever is later <a class="yt-timestamp" data-t="00:41:16">[00:41:16]</a>.

### Monitoring Before Maintenance Dose
Before administering a maintenance dose, three criteria must be fulfilled <a class="yt-timestamp" data-t="00:41:38">[00:41:38]</a>:
1.  Deep Tendon Reflexes (DTR) should be present <a class="yt-timestamp" data-t="00:41:40">[00:41:40]</a>.
2.  Urine output in 4 hours should be more than or equal to 100 mL <a class="yt-timestamp" data-t="00:41:44">[00:41:44]</a>.
3.  Respiratory rate should be more than or equal to 12 breaths per minute <a class="yt-timestamp" data-t="00:41:49">[00:41:49]</a>.

> [!warning] Important
> Renal function (urine output) is *not* checked before giving the loading dose of [[Magnesium sulfate uses in prenatal care | Magnesium sulfate]] <a class="yt-timestamp" data-t="00:41:59">[00:41:59]</a>.

## Anticoagulants in Pregnancy

### Prosthetic Heart Valves
*   **Bioprosthetic Valve:** In pregnancy, only aspirin is given <a class="yt-timestamp" data-t="00:47:35">[00:47:35]</a>.
*   **Mechanical Valve:** Aspirin plus an anticoagulant is given <a class="yt-timestamp" data-t="00:47:43">[00:47:43]</a>. The choice of anticoagulant depends on the period of gestation <a class="yt-timestamp" data-t="00:47:57">[00:47:57]</a>.

| Gestational Age | Anticoagulant Strategy |
| :-------------- | :--------------------- |
| Up to 12 weeks  | Warfarin (if dose < 5mg) OR Low Molecular Weight Heparin (LMWH) (if Warfarin dose â‰¥ 5mg) <a class="yt-timestamp" data-t="00:48:26">[00:48:26]</a> |
| 12 to 36 weeks  | Warfarin (irrespective of dose) <a class="yt-timestamp" data-t="00:48:51">[00:48:51]</a> |
| At 36 weeks     | Switch from Warfarin to Heparin (LMWH) <a class="yt-timestamp" data-t="00:49:06">[00:49:06]</a>. Stop aspirin <a class="yt-timestamp" data-t="00:50:37">[00:50:37]</a>. |
| Day of Delivery | Stop LMWH <a class="yt-timestamp" data-t="00:49:51">[00:49:51]</a>. |
| Post-delivery   | Restart anticoagulation: 6 hours after vaginal delivery or 12 hours after cesarean section <a class="yt-timestamp" data-t="00:50:00">[00:50:00]</a>. Use unfractionated heparin + Warfarin. Unfractionated heparin has easy/quick reversal <a class="yt-timestamp" data-t="00:50:15">[00:50:15]</a>. Withdraw unfractionated heparin when INR is 2.5-3 <a class="yt-timestamp" data-t="00:50:23">[00:50:23]</a>, then continue Warfarin <a class="yt-timestamp" data-t="00:50:31">[00:50:31]</a>. Resume aspirin 6 hours after vaginal delivery or 12 hours after cesarean section <a class="yt-timestamp" data-t="00:50:40">[00:50:40]</a>. |

> [!warning] Warfarin during Labor
> If a patient is on Warfarin at the time of labor or within 2 weeks of delivery, a cesarean section is performed to prevent intracranial hemorrhage in the baby <a class="yt-timestamp" data-t="00:51:11">[00:51:11]</a>.

### [[Medical and Surgical Management of Vascular Diseases | DVT]] in Pregnancy
*   **Management:** Low Molecular Weight Heparin (LMWH), such as Enoxaparin, is used for the management of [[Medical and Surgical Management of Vascular Diseases | DVT]] in pregnancy, irrespective of gestational age <a class="yt-timestamp" data-t="00:51:54">[00:51:54]</a>.

## Hyperthyroidism in Pregnancy

### Drug of Choice
*   **First Trimester:** Propylthiouracil (PTU) is the drug of choice <a class="yt-timestamp" data-t="00:52:08">[00:52:08]</a>.
*   **Second and Third Trimester:** Methimazole or Carbimazole can be used <a class="yt-timestamp" data-t="00:52:14">[00:52:14]</a>.
*   **Thyroid Storm:** Propylthiouracil is the drug of choice for thyroid storm in pregnancy <a class="yt-timestamp" data-t="00:53:35">[00:53:35]</a>. Propranolol can be given for symptomatic relief <a class="yt-timestamp" data-t="00:53:45">[00:53:45]</a>.

> [!warning] Contraindications
> *   Methimazole and Carbimazole are contraindicated in the first trimester because they can lead to aplasia cutis in the fetus <a class="yt-timestamp" data-t="00:53:16">[00:53:16]</a>.
> *   Radioactive iodine is absolutely contraindicated for hyperthyroidism management during pregnancy <a class="yt-timestamp" data-t="00:53:30">[00:53:30]</a>.

> [!info] Fetal Considerations
> *   Fetal thyroid gland starts producing thyroxine from 12 weeks <a class="yt-timestamp" data-t="00:52:19">[00:52:19]</a>.
> *   In the first trimester, the fetus depends on maternal thyroxine <a class="yt-timestamp" data-t="00:52:23">[00:52:23]</a>.
> *   Maternal T3 and T4 can cross the placenta <a class="yt-timestamp" data-t="00:52:34">[00:52:34]</a>.
> *   Maternal TSH cannot cross the placenta <a class="yt-timestamp" data-t="00:52:42">[00:52:42]</a>.
> *   For a hypothyroid patient who conceives, the thyroxine dose should be increased by 30-50% <a class="yt-timestamp" data-t="00:52:28">[00:52:28]</a>.

## Medical Termination of Pregnancy (MTP)

### Methods by Gestational Age
*   **Up to 9 weeks:** Mifepristone and Misoprostol (medical abortion) <a class="yt-timestamp" data-t="01:47:10">[01:47:10]</a>. This is an outpatient procedure <a class="yt-timestamp" data-t="01:48:21">[01:48:21]</a>.
*   **9 to 12 weeks:** Suction evacuation is the best method <a class="yt-timestamp" data-t="01:48:07">[01:48:07]</a>. Suction evacuation can be done up to 16 weeks <a class="yt-timestamp" data-t="01:47:56">[01:47:56]</a>.
*   **Second Trimester (post 12 weeks):**
    *   Prostaglandins (Misoprostol, Carboprost, Dinoprostone) <a class="yt-timestamp" data-t="01:48:33">[01:48:33]</a>.
    *   Oxytocin <a class="yt-timestamp" data-t="01:48:35">[01:48:35]</a>.
    *   Intra-amniotic saline installation <a class="yt-timestamp" data-t="01:48:37">[01:48:37]</a>.
    *   Dilation and evacuation (D&E) <a class="yt-timestamp" data-t="01:48:44">[01:48:44]</a>.
    *   Hysterotomy <a class="yt-timestamp" data-t="01:48:46">[01:48:46]</a>.

## Other Relevant Drug/Management Topics

### IUD in Pregnancy
If pregnancy occurs with an IUD *in situ* and the patient wishes to continue pregnancy, the IUD should be removed if the thread is visible <a class="yt-timestamp" data-t="01:40:42">[01:40:42]</a>. If the thread is not visible, the pregnancy should be continued with the IUD <a class="yt-timestamp" data-t="01:40:49">[01:40:49]</a>.

> [!info] Note
> An IUD is not teratogenic, but its presence is associated with increased chances of infection, abortion, premature rupture of membranes (PROM), and preterm labor <a class="yt-timestamp" data-t="01:40:54">[01:40:54]</a>. If the patient does not wish to continue the pregnancy, the IUD is removed, and an MTP is performed <a class="yt-timestamp" data-t="01:41:05">[01:41:05]</a>.